This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness evidence was derived from a review of completed studies.
Modelling
A decision tree model was constructed to assess the costs and benefits of the two alternative treatment strategies for migraine. Two separate trees were considered for the two strategies.
In the tree for early treatment with sumatriptan, after 2 hours, the patients could:
have resolved their headache and be pain free (but could experience recurrence and require further treatment); progress to persistent mild pain; or develop moderate/severe pain, thus requiring another dose of the same or an alternative medication (thus resolving or not).
For patients who did not resolve, emergency room (ER) or physician visits were considered, while a proportion of patients did not seek medial intervention. The status of the patients was re-evaluated 4 hours after the initial therapy.
The tree for delayed treatment was similar, but the patients did not treat initial mild pain and received sumatriptan only in the case of persistent mild pain or progression to moderate to severe pain (evaluated at 2 and 4 hours).
Outcomes assessed in the review
For early treatment, the outcomes estimated from the literature were the probabilities of the following with a dose of 50 or 100 mg: pain free at 2 hours; moderate/severe pain at 2 hours; persistent mild pain at 2 hours; for those with mild pain at 2 hours, re-treat with sumatriptan or with other medications, or do not treat; for those with mild pain at 2 hours, outcomes of pain free at 4 hours, mild pain at 4 hours, moderate/severe pain at 4 hours;
for those with moderate/severe pain at 2 hours, re-treat with sumatriptan or with other medication, or do not treat;
for those with moderate/severe pain at 2 hours, outcomes of pain free at 4 hours, mild pain at 4 hours, and moderate/severe pain at 4 hours; and recurrence.
For delayed treatment, the probabilities of the following were assessed: to become pain free without treatment, progress to moderate/severe pain, have persistent mild pain; for patients progressing to moderate/severe pain before treatment, outcomes of pain free at 2 hours, moderate/severe pain at 2 hours, mild pain at 2 hours; for those with mild pain at 2 hours, re-treat with sumatriptan or with other medications, or do not re-treat; for those with mild pain at 2 hours, outcomes of pain free at 4 hours, mild pain at 4 hours, and moderate/severe pain at 4 hours; for those with moderate/severe pain at 2 hours, re-treat with sumatriptan or with other medications, or do not re-treat; for those with moderate/severe pain at 2 hours, outcomes of pain free at 4 hours, mild pain at 4 hours, and moderate/severe pain at 4 hours; and recurrence with or without treatment.
Study designs and other criteria for inclusion in the review
A systematic review does not appear to have been conducted. Clinical trials were used to provide the evidence.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
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Methods used to judge relevance and validity, and for extracting data Not stated. However, some of the inputs were obtained from values calculated from the primary data extracted from the trials.
Number of primary studies included
Three primary studies provided the effectiveness evidence.
Methods of combining primary studies
Average values were used, whenever possible, to combine the primary estimates.
Investigation of differences between primary studies
Results of the review
The probability values presented here are for doses of 50 mg (value for 100 mg dose in brackets). A single value refers to both dosages. For delayed treatment, the probabilities were:
0.140 for become pain-free without treatment, 0.580 for progression to moderate/severe pain, 0.280 for have persistent mild pain;
for patients progressing to moderate/severe pain before treatment, 0.290 (0.360) for pain-free at 2 hours, 0.473 (0.465) for moderate/severe pain at 2 hours, 0.237 (0.175) for mild pain at 2 hours;
for those with mild pain at 2 hours, 0.188 for re-treat with sumatriptan, 0.1 for re-treat with other medications, and 0.712 for do not re-treat;
for those with mild pain at 2 hours, 0.455 (0.479) for pain free at 4 hours, 0.182 (0.142) for mild pain at 4 hours, and 0.363 (0.379) for moderate/severe pain at 4 hours;
